β₁ Adrenergic Receptor Autoantibodies and IgG Subclasses: Current Status and Unsolved Issues

Area of Science:

• Cardiology
• Immunology
• Molecular Medicine

Background:

• Autoantibodies against the β1-adrenergic receptor (β1AR-AAb) are implicated in dilated cardiomyopathy (DCM), affecting approximately 40% of patients.
• These antibodies can induce β1AR desensitization, cardiomyocyte apoptosis, and calcium influx, leading to cardiac dysfunction and arrhythmias.

Purpose of the Study:

• To investigate the role of β1AR-AAb IgG subclasses in DCM pathogenesis and treatment response.
• To explore the potential impact of β1AR-AAb IgG subclasses on cardiovascular diseases beyond DCM, including heart failure with preserved ejection fraction.

Main Methods:

• Review of existing clinical research and studies on β1AR-AAb.
• Analysis of the structural and functional differences between IgG subclasses of β1AR-AAb.
• Correlation of β1AR-AAb presence and IgG subclass with clinical outcomes and treatment response (e.g., β-blocker therapy, immunoadsorption).

Main Results:

• The efficacy of immunoadsorption for DCM patients may depend on the removal of specific IgG subclasses, not just total IgG.
• Patient response to β-blocker therapy varies depending on the IgG subclass of β1AR-AAb.
• IgG subclass differences suggest distinct mechanisms of action for β1AR-AAb.

Conclusions:

• Further research is required to understand the pathogenic role of β1AR-AAb IgG subclasses in DCM.
• Investigating β1AR-AAb IgG subclasses could offer new insights into broader cardiovascular diseases, including HFpEF.